Enliven Therapeutics, Inc. (ELVN): Cash & Equivalents
$98.90M
As of 2025-12-31
$135.50M
As of 2026-06-30
+9.4%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $98.90M | -20.3% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $124.12M | +23.9% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $100.14M | +32.6% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $75.54M | n/c | 2024-03-14, Balance as of period end |
| 2021-12-31 | $48.31M | +1.3% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $47.70M | +866.3% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $4.94M | n/a | 2021-03-05, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $98.90M | -20.3% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $46.73M | +22.2% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $46.94M | -23.8% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $229.96M | +132.0% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $373.69M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $52.65M | -7.3% |
Compare ELVN, MPLT, RYTM, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗